Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 894416 + itraconazole
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**BI 894416 + itraconazole** is a combination of a clinical-stage investigational drug (BI 894416, developed by Boehringer Ingelheim) and a widely used antifungal agent, **itraconazole**. While specific details on BI 894416 are limited in public sources, itraconazole is a broad-spectrum triazole antifungal. It inhibits fungal cell membrane synthesis by blocking lanosterol 14-alpha demethylase, an enzyme essential for converting lanosterol to ergosterol, thereby compromising cell membrane integrity[2][5]. Itraconazole is used in the treatment of systemic and superficial fungal infections. This combination may be used in clinical trials to study drug-drug interactions or the effect of CYP3A4 inhibition on the pharmacokinetics of BI 894416, since itraconazole is a potent inhibitor of CYP3A4 and drug transporters like P-glycoprotein[1][5].
- Other names
- BI 894416BI894416BI-894416itraconazole
02
Targets
CYP3A4 (Cytochrome P450 3A4)CYP51A1 (Sterol 14α-demethylase)ABCB1 (P-glycoprotein)PIK3R1 (Phosphatidylinositol 4-phosphate 3-kinase regulatory subunit alpha)STAT3 (Signal Transducer and Activator of Transcription 3)ABCG2 (Breast cancer resistance protein)
Beyond the preview
Go deeper on BI 894416 + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 894416 + itraconazole.